Fennec Pharmaceuticals Inc. reported total net revenues of $9.7 million for the second quarter ended June 30, 2025, representing a 33% increase over the same quarter in 2024. This marks three consecutive quarters of strong performance for the company.
The company achieved double-digit new accounts in Q2 2025, with notable quarter-over-quarter growth in both large community practices and academic centers. This expansion is supported by a refined sales strategy and enhanced patient support services for PEDMARK.
Internationally, PEDMARQSI has seen successful initial uptake in the United Kingdom and Germany, with additional EU launches planned. Results from the investigator-initiated Japan Clinical Trial (STS-J01) are expected in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.